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Abstract DNA of cancers such as renal cell carcinoma and 
mammary invasive ductal carcinoma, is persistently exposed to 
more oxidative stress than that of adjacent nornal tissue. We 
suggest that the concept of ‘persistent oxidative stress in cancer’ 
may open up a new research area, explaining part of the charac- 
teristic tumor biology of cancer such as activated transcription 
factors and proto-oncogenes, genomic instability, chemotherapy- 
resistance, invasion and metastasis. 
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Reactive oxygen species (ROS) are involved in a diversity of 
important phenomena in medicine, such as ischemia-reperfu- 
sion injury, pulmonary oxygen toxicity. atherosclerosis, radia- 
tion effects, chemotherapeutic effects, mutagenesis, carcino- 
genesis and aging [I]. In this paper, we hypothesize a role for 
ROS in the biology of malignant neoplasia, especially 
adenocarcinoma. 
Among the targets of ROS, DNA appears most important 
in tumor biology since it is firmly established that cancer is a 
genetic disease [2]. ROS induce several kinds of DNA damage, 
including strand breakage, base modification and DNA-pro- 
tein cross-linkage [3]. 8-Hydroxy-2’-deoxyguanosine (8-OH- 
dG, also known as 7,8-dihydro&oxo-2’-deoxyguanosine) [4] is 
one of the major oxidatively modified DNA base products in 
vivo [3,5], is mutation-prone (G:C to T:A transversion) [6,7] 
and is easily detected by high performance liquid chromatogra- 
phy combined with an electrochemical detector [3]. It is known 
that either the hydroxyl radical (‘OH), singlet oxygen or photo- 
dynamic action is responsible for the formation of 8-OH-dG 
PA. 
We have recently reported that human renal cell carcinomas 
have a higher content of 8-OH-dG than adjacent non-tumorous 
renal tissue [9]. Tables 1 and 2 summarize the published data. 
Similar results have been found in tumors of other organs. Four 
independent groups of investigators showed a higher content 
of 8-OHdG in human tumors by the use of two different meth- 
ods. This indicates that DNA of neoplasm, especially 
adenocarcinoma, is more exposed to ROS than its non-tu- 
morous counterpart. 
What kind of cells produce ROS in this situation? Cancer 
cells themselves, endothelial cells or macrophages are major 
candidates. Based on our renal cell carcinoma immunohisto- 
chemical study of lipid peroxidation products (4-hydroxy-2- 
nonenal-modified proteins), we believe that cancer cells them- 
selves produce ROS, at least in human renal cell carcinoma. 
Lipid peroxidation products were demonstrated in the cyto- 
plasm of renal cell carcinoma cells with a granular pattern [9]. 
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It is reasonable to suppose that membrane lipids near the ROS 
generation site are the most severely damaged. 
The metabolism of ROS in cancer cells is a research area that 
has not been intensively pursued. The first important question 
is whether cancer cells produce larger amounts of ROS than 
non-neoplastic cells or whether the antioxidant system of can- 
cer cells is suppressed. There is evidence favoring both mecha- 
nisms. Large amounts of hydrogen peroxide are reportedly 
produced in vitro without exogenous stimulation in several 
human carcinoma cell lines, including malignant melanoma, 
colon carcinoma, pancreatic carcinoma, neuroblastoma. breast 
carcinoma and ovarian carcinoma [IO]. A flavoprotein and/or 
a nucleoside oxidase may be involved in the mechanism of Hz02 
production [lo]. Hydrogen peroxide freely passes through 
membranes and can reach any cellular compartment [ 11. Since 
‘OH is very reactive, essentially reacting at the site of its gener- 
ation. it is likely that ‘OH is produced from HzO, in the pres- 
ence of intracellular ‘catalytic’ iron or copper through the Fen- 
ton reaction [I I] to induce 8-OH-dG formation and lipid perox- 
idation [I]. Indeed, ‘OH generation in human cancers is con- 
firmed by the fact that the spectrum of modified DNA bases 
induced was that of ‘OH attack [12,13]. 
On the other hand, catalase gene expression is reportedly 
negatively regulated in human hepatoma cells [14]. Indeed. 
tumor cells are always low in manganese superoxide dismutase 
activity, usually low in copper and zinc superoxide dismutase 
activity, and almost always low in catalase activity. The activity 
of glutathione peroxidase and glutathione reductase is highly 
variable [l5]. The amount of H202 or superoxide contained in 
tumor cells should be raised by this regulation. However. the 
antioxidant system is complicated. For example, glutathione 
peroxidase has catalase activity and may functionally compen- 
sate for lack of catalase. 
In spite of evidence that cancer cells are oxidatively stressed 
(Tables I and 2), the stress is usually insufficient to cause cell 
death. A rapid and pronounced increase in 8-OH-dG content 
and 4-hydroxy-2-nonenal-modified proteins was associated 
with cell death in our experimental ROS-induced renal carcin- 
ogenesis model using ferric nitrilotriacetate [5,16]. Some tumor 
cells are resistant to oxidative cytolysis [ 171, and adenocarcino- 
mas in general, especially renal cell carcinomas, are highly 
chemotherapy-resistant [18]. Accordingly. cancer cells should 
have mechanisms, other than the antioxidant enzymes men- 
tioned above, to resist increased oxidative stress. Three possible 
candidates are adult T-cell leukemia-derived factor (ADF), glu- 
tathione-S-trdnsferase n (GST-P) and glutathione. ADF is a 
human thioredoxin homologue with many functions, including 
interleukin-2 receptor induction, thiol-dependent reducing ac- 
tivity, radical scavenging activity [I91 and NF-KB activation 
[20]. Recently, it was found that a variety of human cancers, 
including adult T-cell leukemia, squamous cell carcinoma of the 
uterine cervix [2l] and hepatocellular carcinoma [22]. show 
increased amounts of ADF. GST-P, also increased in cancers 
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Table 1 
Content of 8-hydroxy-2’-deoxyguanosine in human carcinoma (multiple case study) 
Organ Histology Control Tumor n; statistics Method Reference 
Breast Invasive ductal carcinoma 4.13 ? 0.43 40.1 f 11.1 (5; P < 0.01) GUMS [331 
Lung Squamous cell carcinoma 11.2 f 2.3 25.5 + 7.0 (5; P < 0.05) GUMS ]I31 
Liver Hepatocellular carcinoma 1.57 f 0.21 2.29 2 0.38 (11, 18; P = 0.174) HPLUECD [34] 
Kidney Renal cell carcinoma 3.60 f 0.20 5.56 + 0.41 (31; P < 0.0005) HPLCIECD [ 91 
The amount of &hydroxy-2’-deoxyguanosine per 10’ deoxyguanosine in DNA is shown by means ? S.E.M. Some of the data were modified for unity. 
All the samples except those from [34] are paired samples from the same patient. The patients were all heavy smokers [13]. Control liver samples 
were from patients with metastatic liver tumors [34]. GUMS, gas chromatography with mass spectrometry; HPLUECD, high performance liquid 
chromatography with electrochemical detector. 
[23] and in the serum of cancer patients [24], is induced upon 
oxidative stress and is associated with chemoresistance [25,26]. 
Glutathione, a tripeptide thiol present in virtually all animal 
cells, is also synthesized by tumors. For example, infiltrating 
ductal breast carcinoma has more than twice the levels of glu- 
tatione found in normal breast tissue [27]. 
What is the significance of persistent oxidative stress in can- 
cer? First, it may constantly activate transcription factors, such 
as NF-KB, through the intracellular signal transduction system 
[28] and induce expression of proto-oncogenes such as c-j&, 
c-&n and c-myc [29,30]. Secondly, oxidative stress induces 
DNA damage such as modified base products and strand 
breaks that may lead to further mutation and chromosomal 
Table 2 
Content of S-hydroxy-2’-deoxyguanosine in human neoplasm (single 
case study) 
Organ Histology Control Tumor 
Brain Fibrillary astrocytoma 1.36 2.49 
Lung Squamous cell carcinoma 9.68 10.1 
Lung Adenocarcinoma 7.33 23.0 
Colon Non-primary carcinoma 2.11 4.43 
Stomach Mutinous carcinoma 0.94 5.08 
Ovary Serous cvstadenocarcinoma 3.11 9.20 
Data based on GUMS method are from [12]. The amount of 8-hy- 
droxy-2’-deoxyguanosine per 10’ deoxyguanosine in DNA is shown. 
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Fig, 1. Schematic outline of the role of reactive oxygen species in cancer. SOD, superoxide dismutase; ‘OH, hydroxyl radical; ADF, adult T-cell 
leukemia-derived factor; GST, glutathione S-transferase: GSH, glutathione. 
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aberration of cancer (genomic instability) [13]. Thirdly, it can 
activate specific antioxidant systems in cancer cells that may 
make cancer cells resistant to chemotherapy. Indeed, bleomy- 
tin and doxorubucin are known to function as antitumor 
agents by producing ROS in the target tissue [l]. Finally, ROS 
can specifically damage certain protease inhibitors, including 
cr,-proteinase inhibitor, qmacroglobulin, plasminogen activa- 
tor inhibitor and qplasmin inhibitor by oxidizing methionine 
residues of the active site [31,32]. Inactivation of these protein 
inhibitors could induce enhanced action of proteases, such as 
elastase, plasminogen activator and plasmin. This may facilitate 
tumor invasion and metastasis [lo]. 
Our hypothesis of a role for ROS in tumor biology is summa- 
rized in Fig. 1. We believe that persistent oxidative stress may 
partly explain the characteristics of cancer, such as activated 
proto-oncogenes and transcription factors, genomic instability, 
chemotherapy-resistance, invasion and metastasis. Further 
study is necessary to establish the role of ROS in tumor biology 
and to prove that this hypothesis can be applied to various 
kinds of malignant tumors. 
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